Hoffman Robert E. 4

What Happened

Robert E. Hoffman, a director of Esperion Therapeutics (ESPR), was granted 79,873 shares on 2026-05-28 as an award (reported as code A). The shares were issued at $0.00 per share (total reported value $0) — this is a compensatory equity grant rather than a purchase or sale.

Key Details

• Transaction date: 2026-05-28 (reported on Form 4 filed 2026-06-01).
• Transaction type/code: Award/Grant (A).
• Shares granted: 79,873; Price per share: $0.00; Reported total value: $0.
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Vesting/footnote: The award vests in full on the earlier of (i) May 28, 2027 or (ii) the issuer's next annual meeting of stockholders following May 28, 2026 (Footnote F1).
• Timeliness: Filing dated 2026-06-01 appears to meet the Form 4 two-business-day reporting requirement for a 2026-05-28 transaction.

Context

This is a typical director compensation grant — shares are subject to vesting and were issued at $0, so it is not a market purchase. Such grants compensate service and do not, by themselves, indicate that the insider is buying or selling based on valuation expectations. Monitor future Form 4s for vesting events, sales, or other dispositions if you want to track when the shares become liquid.